Attendees got a glimpse of thoracic oncology’s future in Seoul, South Korea, during the IASLC 2026 World Conference on Lung Cancer (WCLC). On top of key therapeutic advances in the non–small cell lung cancer (NSCLC) space, experts shared critical updates that may influence small cell lung cancer (SCLC) management. Considering new data on modalities like B7-H3–directed antibody drug conjugates (ADCs) and brain MRI surveillance, SCLC has “been on a tear lately,” as Benjamin Herzberg, MD, an assistant professor of Medicine at Columbia University Medical Center and associate director of the Experimental Therapeutics/Phase I Program at Herbert Irving Comprehensive Cancer Center, described.
